| Recruitment status | No longer recruiting |
| Unique ID issued by UMIN | UMIN000006487 |
| Receipt No. | R000007697 |
| Official scientific title of the study | Multicenter phase II study of oral S-1 monotherapy in advanced colorectal cancer who have failed prior oxaliplatin and irinotecan-based therapies |
| Date of disclosure of the study information | 2011/10/06 |
| Last modified on | 2016/11/16 (Ver. 10) |
| Basic information | ||
| Official scientific title of the study | Multicenter phase II study of oral S-1 monotherapy in advanced colorectal cancer who have failed prior oxaliplatin and irinotecan-based therapies | |
| Title of the study (Brief title) | Multicenter phase II study of oral S-1 monotherapy in advanced colorectal cancer who have failed prior oxaliplatin and irinotecan-based therapies
<CCOG-1103 (C3-01)> |
|
| Region |
|
|
| Condition | |||
| Condition | Colorectal cancer | ||
| Classification by specialty |
|
||
| Classification by malignancy | Malignancy | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To evaluate the efficacy and safety of oral S-1 monotherapy in advanced colorectal cancer who have failed prior oxaliplatin and irinotecan-based therapies |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Phase II |
| Assessment | |
| Primary outcomes | Progression free survival |
| Key secondary outcomes | One year survival rate, Overall survival, Response rate, Disease control rate, Time to treatment failure, Toxicity |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | S-1 monotherapy | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | (1) Histopathologically confirmed colorectal cancer
(2) Unresectable advanced colorectal cancer patients who have failed prior oxaliplatin and irinotecan-based therapies (3) Measurable or evaluable disease (RECIST ver.1.1.) (4) Colorectac cancer with Kras mutant type gene (5) Age of 20 years or older (6) ECOG performance status 0-1 (7) Alife expectancy greater than 3 months (8) Written informed concent (9) Adequate organ function |
|||
| Key exclusion criteria | (1) Uncontrolled infection.
(2) Patient with symptomatic cardiovascular disease or asymptomatic disease but have been treated (>=Grade 2 according to NCI-CTCAE ver.4). History of myocardial infarction within a year. (3) Severe lung disease. (4) Interstitial lung disease or pulmonary fibrosis. (5) Severe liver disease. (6) Severe renal failure, or urinary protein (more than 2+). (7) Previous history of severe drug-induced allergy (8) ileus, bowel obstruction (9) Uncontrolled severe complications (DM, hypertension, diarrhea, et al.). (10) History of active double cancer. (11) Massive pleural effusion or ascites that required drainage. (12) Brain metastasis (13) Pregnant women, possibly pregnant women, wishing to become pregnant, and nursing mothers. (14) Not appropriate for the study at the physician's assessment. |
|||
| Target sample size | 34 | |||
| Research contact person | |
| Name of lead principal investigator | Goro Nakayama |
| Organization | Nagoya University Gradeate School of Medicine |
| Division name | Department of Gastroenterology |
| Address | 65,turumaityou,syouwaku,nagoya city |
| TEL | 052-744-2250 |
| goro@med.nagoya-u.ac.jp | |
| Public contact | |
| Name of contact person | Takahiro Asada, Koji Torii |
| Organization | Nagoya University Gradeate School of Medicine |
| Division name | Department of Gastroenterology |
| Address | 65,turumaityou,syouwaku,nagoya city |
| TEL | 052-744-2250 |
| Homepage URL | http://www.med.nagoya-u.ac.jp/surgery2/scientific/ccog/ |
| goro@med.nagoya-u.ac.jp | |
| Sponsor | |
| Institute | Chube Clinical Oncology Group (CCOG) |
| Institute | |
| Department | |
| Funding Source | |
| Organization | None |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | No longer recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000007697 |